Coverage Initiated by Mizuho for Atara Biotherapeutics (NASDAQ:ATRA)

Stock analysts at Mizuho initiated coverage on shares of  Atara Biotherapeutics (NASDAQ:ATRA) in a report issued on wednesday. The brokerage set a Buy rating on the Medical stock. A price-to-earnings ratio of #N/A and a beta of 2.27. Atara Biotherapeutics has a twelve month low $11.81 of  and a twelve month high of $28.20.

Shares of Atara Biotherapeutics traded down -$2.32 on wednesday, reaching $15.66. 1837935 shares of the stock traded hands, compared to its average volume of 838230. Shares of Atara Biotherapeutics were trading at $15.66 on wednesday. The firm’s 50 day moving average is $$15.18 and its 200 day moving average is $15.55.Atara Biotherapeutics  has a 12 month low of $15.34 and a 12 month high of $28.20. While on yearly highs and lows, Atara Biotherapeutics’s today has traded high as $17.97 and has touched $15.34 on the downward trend. See More Analyst Rating at: RATING

Atara Biotherapeutics Earnings and What to expect: 

Atara Biotherapeutics last announced its quarterly earnings results on August 8th, 2021. The biotechnology company reported ($0.91) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.88) by $0.03. The firm had revenue of $3.87 million for the quarter, compared to analyst estimates of $6.32 million. Atara Biotherapeutics has generated ($4.15) earnings per share over the last year (($3.64) diluted earnings per share). Earnings for Atara Biotherapeutics are expected to decrease in the coming year, from ($3.38) to ($3.42) per share. Atara Biotherapeutics has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Monday, November 8th, 2021 based off prior year’s report dates.

Earnings for Atara Biotherapeutics are expected to decrease in the coming year, from ($3.38) to ($3.42) per share. The P/E ratio of Atara Biotherapeutics is -4.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Atara Biotherapeutics is -4.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Atara Biotherapeutics has a P/B Ratio of 2.63. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Atara Biotherapeutics (NASDAQ:ATRA) Moving Average Technical Analysis

5 day Moving Average is $17.05 And 5 day price change is -$1.75 (-10.05%)  with average volume for 5 day average is 961,640. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $17.05 and 20 day price change is -$0.24 (-1.51%) and average 20 day moving volume is 912,290. 50 day moving average is $15.18  and 50 day price change is $3.07 ( 24.38%)  and with average volume for 50 days is : 783,044. 200 day moving average is $15.55  and 200 day price change is -$5.50 (-25.99%)  and with average volume for 200 days is : 848,243.

Other owners latest trading in Atara Biotherapeutics :

  • On 9/17/2021 shares held by Virtu Financial LLC were 12,680 which equates to market value of $0.20M and appx 0.00% owners of Atara Biotherapeutics
  • On 9/3/2021 shares held by Parametric Portfolio Associates LLC were 58,027 which equates to market value of $0.90M and appx 0.00% owners of Atara Biotherapeutics
  • On 8/23/2021 shares held by Morgan Stanley were 3,035,747 which equates to market value of $47.21M and appx 0.00% owners of Atara Biotherapeutics
  • In total Institutional ownership equates to There is no enough data Institutional Ownership Percentage for Atara Biotherapeutics

See More Analyst Rating at: RATING